Kamada Ltd. KMDA reports that the
pivotal Phase 2/3 clinical trial with the Company's human rabies immune
globulin (IgG or KamRAB™ or KedRAB™) therapy as a post-exposure
treatment for rabies successfully met the trial's primary endpoint of
non-inferiority when measured against an IgG reference product. The
Company expects to file a Biologics License Application (BLA) with the
U.S. Food and Drug Administration (FDA) in mid-2016.
KamRAB is the brand name for Kamada's human rabies immune globulin
currently marketed for this indication in 10 countries worldwide. Kamada
has a strategic agreement with Kedrion S.p.A for the clinical
development and marketing of its IgG product,
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in